Trial Profile
Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Expanded access; Therapeutic Use
- 14 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2020 Planned End Date changed from 21 Jul 2025 to 31 Jul 2025.
- 23 Apr 2020 Planned primary completion date changed from 21 Jul 2025 to 31 Jul 2025.